Newsletter | November 18, 2026

11.18.26 -- Sustainability In Manufacturing: Power And Digital Twins

SPONSOR

Webinar: Building for What Comes Next: Robust Process Development and Analytical Strategies in Early Pharmaceutical Development

Successful drug development starts with strong collaboration between process and analytical teams. Join Cambrex experts to explore proven strategies, real-world case studies and best practices for reducing development risks, improving process robustness and supporting scale-up. Discover how early integration and external expertise can accelerate development, strengthen decision-making and improve the path to commercialization. Click here to learn more.

INDUSTRY INSIGHTS

Why Controlled Release Is Essential For Patient-Centric Drug Development

Controlled release design can ease daily dosing burden by moderating swings in drug exposure, though the right approach depends on API properties and what manufacturing can deliver at scale.

Formulation And Process Challenges For A Needle-Shaped API

Managing challenging active pharmaceutical ingredient crystal structures and choosing dry granulation over wet granulation requires strategic processing choices.

Secondary Packaging: Cartoning And Kitting With An Aggressive Timeline

Meeting tight launch timelines requires more than speed. Smart kit design, controlled production workflows, and scalable processes come together to deliver complex packaging programs quickly.

FEATURED EDITORIAL

Sustainability In Manufacturing: Power And Digital Twins

Heather Walters of CRB spends her time thinking about effective business and industrial sustainability and resource conservation. Meanwhile, Chief Editor Louis Garguilo maintains a position near the bottom of the list of interested parties. It made for great conversation. Uncovered were the current realities of sustainability in manufacturing facilities, and the importance of two components: electrification and digital twins.

Developing Your Vapor Phase Hydrogen Peroxide Cycle

Vapor phase hydrogen peroxide has been used for decades as a surface decontaminant in pharma/biotech, but there has been little guidance on how to establish the parameters. Here's an industry consensus from BioPhorum.

INDUSTRY INSIGHTS CONTINUED

Overcoming Food Effects For A Non-Opioid Analgesic

Develop optimized lipid-based formulations to overcome solubility, stability, and food-effect challenges, enabling high-dose oral delivery and rapid progression to Phase 1 trials.

Don't Let Formulation Failures Derail Drug Development

In the face of increasing molecular complexity, early developability assessment with a skilled CDMO can reduce pharmaceutical development costs, prevent clinical delays, and improve commercial success.

Silencing CDMO Project Noise: The Power Of Low-Drama Drug Development

Move beyond reactive firefighting by prioritizing disciplined leadership and data-driven milestones. The winning model for complex programs is focused, high-maturity, low-drama execution.

Work With An In-Country Depot For Efficiency And Compliance

If you’re launching an international clinical trial, consider the noteworthy benefits of partnering with an in-country depot, including increased efficiency, reduced costs, and reliable access to raw materials.

Antibiotic Potency Testing By Microbial Assay

Selecting a potency assay for antibiotic drug substances and products carries regulatory, operational, and lifecycle implications that extend well beyond the laboratory.

Ask Us Anything: Jillian Sheeran On Emerging Reactor Technologies

Jillian Sheeran, Associate Director of Engineering at Snapdragon Chemistry, on how automation, feedback control, and machine learning are changing reactor design.

Peptide Building Blocks: Navigating Quality, Supply, And Scale

Non-canonical amino acids can boost peptide half-life and potency, but create challenges in impurity control, GMP classification, and sourcing. Early supplier choices are critical for commercialization.

SPONSOR

Enabling ADC Success | Dec. 1, 2026, 11:00 AM ET

This session explores the development, analytical, and manufacturing strategies supporting antibody-drug conjugate (ADC) and emerging conjugate programs. CDMOs will discuss challenges related to conjugation, CMC, developability, lyophilization, and complex payloads, including antibody-oligonucleotide conjugates. Attendees will gain insights into early risk mitigation, optimization strategies, and science-driven approaches that help improve program success and support efficient development and manufacturing. Learn more.

SOLUTIONS

Scaling Difficult Chemistry Without Site Transfers

The Future Of Amorphous Solid Dispersions

Oral Solid Dosage Development And Manufacturing

Getting Solid Form Right The First Time

How A Drug Development Model Enhances eNPV

Solutions For Your Oral Dose Challenges

OUTSOURCED PHARMA CAPABILITIES UPDATE

Find Your New CDMO At Outsourced Pharma Capabilities Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: